Jeanne Charleston.

Lawrence J. Appel, M.D More information here ., M.P.H., Jackson T. Wright, Jr., M.D., Ph.D., Tom Greene, Ph.D., Lawrence Y. Agodoa, M.D., Brad C. Astor, M.P.H., Ph.D., George L. Bakris, M.D., William H. Cleveland, M.D., Jeanne Charleston, R.N., Gabriel Contreras, M.D., M.P.H., Marquetta L. Faulkner, M.D., Francis B. Gabbai, M.D., Jennifer J. Gassman, Ph.D., Lee A. Hebert, M.D., Kenneth A. Jamerson, M.D., Joel D. Kopple, M.D., M.P.H., John W. Kusek, Ph.D., James P. Lash, M.D., Janice P. Lea, M.D., Julia B. Lewis, M.D., Michael S. Lipkowitz, M.D., Shaul G. Massry, M.D., Edgar R. Miller, Ph.D., M.D., Keith Norris, M.D., Robert A. Phillips, M.D., Ph.D., Velvie A.

Among the ladies who met the criteria for the primary end result, 164 had severe hypertension only and 321 had preeclampsia . No benefit of therapy was seen in women with severe pregnancy-associated hypertension or slight preeclampsia with among the primary outcome components . Two women died from peripartum cardiomyopathy. Rates of adverse neonatal outcomes also did not differ significantly between your groups . We performed 1 post hoc subgroup evaluation based on the week of being pregnant at randomization . Among the 4343 ladies who entered the analysis before the 13th week of being pregnant, the primary outcome occurred in 6.6 percent of those in the vitamin group, as compared with 5.9 percent of these in the placebo group ; among the 5626 women who have been enrolled in or following the 13th week of pregnancy, the primary outcome occurred in 5.7 percent of these in the vitamin group and 5.6 percent of these in the placebo group .